Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL)

Market Open
18 Aug, 15:11
NYSE NYSE
$
285. 12
-1.52
-0.5303%
$
13.55B Market Cap
- P/E Ratio
- Div Yield
149,486 Volume
- Eps
$ 286.64
Previous Close
Add Transaction
Day Range
284.94 289.6
Year Range
144.26 289.6
Want to track CRL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Charles River Q2 Earnings Preview: What's in Store for the Stock?

Charles River Q2 Earnings Preview: What's in Store for the Stock?

CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.

Zacks | 1 year ago
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?

Is it Prudent to Retain Charles River Stock in Your Portfolio Now?

CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.

Zacks | 1 year ago
Creightons shares fall 10% as cautious outlook tempers improved results

Creightons shares fall 10% as cautious outlook tempers improved results

Shares in Creightons PLC (LSE:CRL) dropped 10% on Wednesday despite reporting a return to profitability, as investors reacted to a cautious outlook for the year ahead. The beauty and personal care manufacturer posted a 1.6% rise in revenue to £54.1 million for the year to 31 March 2025, with strong growth in private label sales offsetting declines in branded and contract manufacturing.

Proactiveinvestors | 1 year ago
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

RARE faces regulatory setback as FDA issues a CRL for UX111, delaying approval of the MPS IIIA gene therapy until 2026.

Zacks | 1 year ago
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Charles River Stock May Gain From Extended CHDI Research Deal on HD

Charles River Stock May Gain From Extended CHDI Research Deal on HD

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Zacks | 1 year ago
Should You Continue to Hold Charles River Stock in Your Portfolio?

Should You Continue to Hold Charles River Stock in Your Portfolio?

CRL stays on investors' radars due to the strength of partnerships and segmental prospects.

Zacks | 1 year ago
Understanding Charles River (CRL) Reliance on International Revenue

Understanding Charles River (CRL) Reliance on International Revenue

Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Zacks | 1 year ago
Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

The firm has three possible paths toward value creation at the drug development company.

Cnbc | 1 year ago
S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.

Investopedia | 1 year ago
Loading...
Load More